Canagliflozin boosts A1C, beta-cell function in type 2 diabetes

05/6/2013 | Healio

Type 2 diabetes patients who used canagliflozin as an add-on to metformin/sulfonylurea treatment showed better A1C rates at 26 weeks compared with those in the placebo group, a study indicated. Researchers also noted improvements in insulin secretion rates and beta-cell function among canagliflozin-treated patients. The findings were presented at the American Association of Clinical Endocrinologists annual meeting.

View Full Article in:

Healio

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY